Saturday 17 October 2026
Export BLTE’s income statement to Excel — free account
Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 40.0% and free cash flow grew 64.7%, each against the same quarter a year earlier.
142.78
9.84
−6.45%
Follow BLTE
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
Current Ratio |
50.02 | 24.31 | 24.76 | 20.35 | 10.66 | 26.41 |
Net Debt/EBITDA |
5.88 | 3.67 | 2.82 | 3.33 | 1.78 | 4.47 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.48 | 0.81 | 0.94 | 0.91 | 0.77 | 0.77 |
Capex/Depreciation |
(0.38) | (0.34) | (0.16) | (1.99) | (1.87) | (1.18) |
Interest Coverage |
(42,104.00) | (1,999.80) | (1,266.72) | (801.31) | (1,959.40) | (273.48) |
| (16.94%) | (30.60%) | (47.95%) | (95.79%) | 87.36% | 0.00% | |
| (16.64%) | (29.29%) | (45.54%) | (40.40%) | (43.85%) | 0.00% | |
ROIC |
(18.93%) | (3,719.87%) | (870.38%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(16.01%) | (25.55%) | (36.44%) | (30.67%) | (60.83%) | (23.25%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(1.11) | (0.96) | (1.12) | (0.59) | (0.79) | (0.51) |
Cash per Share |
14.68 | 4.75 | 3.31 | 2.11 | 1.81 | 2.91 |
Shareholders Equity per Share |
22.97 | 4.78 | 3.40 | 2.08 | (1.58) | (0.80) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
22.97 | 4.78 | 3.40 | 2.08 | (1.58) | (0.80) |
Free Cash Flow |
(37.17) | (29.38) | (29.90) | (11.85) | (7.53) | (4.46) |
Working Capital |
484.39 | 141.02 | 86.31 | 40.70 | 15.80 | 24.70 |
Capital Expenditures |
(0.18) | (0.15) | (0.06) | (0.39) | (0.06) | (0.02) |
Net Current Asset Value |
484.20 | 140.76 | 85.73 | 40.04 | (16.01) | (7.11) |
| Other line items | ||||||
Quick Ratio |
49.90 | 24.09 | 24.50 | 20.01 | 10.62 | 26.40 |
Depreciation/Fixed assets |
1.35 | 1.01 | 0.81 | 0.37 | 0.32 | 0.37 |
Cash ROIC |
(2.94%) | (10.10%) | (16.74%) | (14.18%) | (334.52%) | (24.01%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | — | — | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.10) | (0.96) | (1.12) | (0.57) | (0.78) | (0.51) |
Capex per Share |
(0.01) | 0.00 | 0.00 | (0.02) | (0.01) | 0.00 |
Average Receivables |
0.64 | 0.71 | 0.42 | 0.01 | 0.03 | — |
Average Assets |
466.34 | 123.39 | 69.46 | 31.31 | 22.04 | — |
Average Common Equity |
458.15 | 118.13 | 65.97 | 13.20 | (11.06) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates